American Well vs Sophia Genetics SA
American Well is the larger business, with $249m of revenue in fiscal 2025 against $77.3m for Sophia Genetics SA (3.2 times as much). Sophia Genetics SA grew faster (18.6% against -2.0%). American Well kept more of each dollar of sales as profit: a net margin of -38.4% against -102.2%.
| Latest fiscal year | American WellAMWL, 2025 | Sophia Genetics SASOPH, 2025 |
|---|---|---|
| Revenue | $249m | $77.3m |
| Revenue growth | -2.0% | 18.6% |
| Net income | −$95.7m | −$79.0m |
| Operating margin | — | -91.8% |
| Net margin | -38.4% | -102.2% |
| Return on equity | -35.4% | -110.0% |
| Free cash flow | −$66.0m | −$36.5m |
| Cash | $182m | $70.3m |
| Total debt | $0 | $47.7m |
| Debt to equity | — | 101.2% |
| Dividend per share | — | — |
| Dividend yield | — | — |
| Share buybacks | $4,000 | — |
| Employees | 562 | — |
| Market value | $215m | $460m |
| Price vs our value range | — | — |
| Moat score | 12 (Weak) | — |
| Insider trades, 12 months | 1 buys, 29 sales | 1 buys, 150 sales |